Western Kentucky University

TopSCHOLAR®
Masters Theses & Specialist Projects

Graduate School

Fall 2015

Expression and Purification of Unlabelled and
Isotopically Labelled Human Fibroblast Growth
Factor-1 and its Receptor Relevance in Cancer
Research
Oluwadamilola Filani
Western Kentucky University, oluwadamilola.filani259@topper.wku.edu

Follow this and additional works at: http://digitalcommons.wku.edu/theses
Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cell and Developmental
Biology Commons, and the Chemistry Commons
Recommended Citation
Filani, Oluwadamilola, "Expression and Purification of Unlabelled and Isotopically Labelled Human Fibroblast Growth Factor-1 and
its Receptor Relevance in Cancer Research" (2015). Masters Theses & Specialist Projects. Paper 1549.
http://digitalcommons.wku.edu/theses/1549

This Thesis is brought to you for free and open access by TopSCHOLAR®. It has been accepted for inclusion in Masters Theses & Specialist Projects by
an authorized administrator of TopSCHOLAR®. For more information, please contact topscholar@wku.edu.

EXPRESSION AND PURIFICATION OF UNLABELLED AND ISOTOPICALLY
LABELLED HUMAN FIBROBLAST GROWTH FACTOR-1 AND ITS RECEPTORRELEVANCE IN CANCER RESEARCH

A Thesis Presented to
The Faculty of the Department of Chemistry
Western Kentucky University
Bowling Green, Kentucky

In Partial Fulfillment
Of the Requirements for the Degree
Master of Science

By
Oluwadamilola Filani
December 2015

ACKNOWLEDGEMENTS

I am most grateful to God Almighty for His grace to complete this program and thesis.
This thesis would not have been possible without the help of several individuals that
extended their valuable assistance completion of this project. First and foremost, my
sincere gratitude to Dr. Rajalingam Dakshinamurthy, my research supervisor who’s
detailed and constructive guidance and encouragement has been an inspiration all
through this program.

I would also like to thank Dr. Stuart Burris, Chair of the Department of Chemistry and
my committee members: Dr. Cathleen Webb and Dr. Kevin Williams. I would also like
to thank the faculty and staff of the Department of Chemistry for their support in my
graduate career at Western Kentucky University.

I thank my colleagues Tulsi Modi, Sarah Tockstein, Will Hamiton and Jason Payne for
their support during my times in the lab and for their help with editing.

Finally, I thank the Filanis, Adebanjos and Akintobi Akinwumi for been a great support
during my challenging moments.

iii

TABLE OF CONTENTS

Introduction ........................................................................................................................ 1
Material and Methods ...................................................................................................... 15
Results and Discussion .................................................................................................... 31
Conclusions ...................................................................................................................... 47
Future Studies .................................................................................................................. 48
References ........................................................................................................................ 49

iv

LIST OF FIGURES
Figure 1. Cancer Mortality Worldwide .............................................................................. 2
Figure 2. Three Dimensional Structure of hFGF-1 ............................................................ 6
Figure 3. Schematic Structure of FGFR ............................................................................ 8
Figure 4. Heparan sulfate ................................................................................................. 10
Figure 5. Signaling Mechanism of FGFs ......................................................................... 12
Figure 6. Schematic representation of hFGF-1 expression .............................................. 24
Figure 7. Schematic representation of hFGF-1 purification ............................................ 25
Figure 8. Schematic representation of D2 expression ..................................................... 28
Figure 9. Schematic representation of D2 purification .................................................... 29
Figure 10. Making NMR active hFGF-1 molecules ........................................................ 31
Figure 11. SDS-PAGE analysis of hFGF-1 expression ................................................... 34
Figure 12. SDS-PAGE analysis of hFGF-1 purification ................................................. 35
Figure 13. SDS-PAGE analysis of D2 domain expression .............................................. 38
Figure 14. SDS-PAGE analysis of D2 domain purification ............................................ 39
Figure 15. SDS-PAGE analysis of 15N labelled hFGF-1 expression ............................... 41
Figure 16. SDS-PAGE analysis of 15N labelled hFGF-1 purification ............................. 42
Figure 17. Intrinsic fluorescence spectra for hFGF-1 ...................................................... 44
Figure 18. Intrinsic fluorescence spectra for D2 domain ................................................ 45
Figure 19. 1H-15N HSQC spectrum conformation of hFGF-1 ......................................... 47

v

LIST OF TABLES
Table 1. Chemicals used in this study . ............................................................................ 12

vi

EXPRESSION AND PURIFICATION OF UNLABELLED AND ISOTOPICALLY
LABELLED HUMAN FIBROBLAST GROWTH FACTOR-1 AND ITS RECEPTOR RELEVANCE IN CANCER RESEARCH
Oluwadamilola Filani

51 Pages

December 2015

Directed by: Rajalingam Dakshinamurthy, Cathleen Webb, and Kevin Williams
Department of Chemistry

Western Kentucky University

Studies show that fibroblast growth factors (FGFs) control variety of cellular activities
such as mitosis, cell differentiation, survival and angiogenesis. The FGF family consists
of 23 different heparin-binding proteins. One of the most intensively studied members is
human FGF-1 (hFGF-1) because of its critical role in the formation of blood vessels and
cell proliferation in some types of cancer. The biological activities of FGFs are primarily
mediated via interactions with fibroblast growth factor receptors (FGFR) and are a potent
target in cancer. In this study, we report an efficient affinity column purification of
hFGF-1 and the D2 domain of FGFR-2 from bacterial expression followed by SDSPAGE analysis. Steady state fluorescence results showed that both proteins were in their
native conformation. The
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H-15N HSQC NMR analysis of hFGF-1 was further

performed. The data confirmed the purity and well-conserved native state of the protein.
The findings of this study can be used in designing hFGF-1 antagonists with competitive
inhibition characteristics. These antagonists could result in possible inhibition of hFGF-1
cell proliferation and angiogenesis associated in tumorigenesis.

vii

INTRODUCTION
Cancer
In recent times, cancer has become a worldwide concern affecting almost all
countries. According to worldwide statistics collected by the World Health Organization
(WHO) in 2012, there were about 14.1 million new people diagnosed with cancer, and
approximately 8.2 million deaths caused by cancer (Fig. 1).1 Cancer is a class of complex
genetic diseases characterized by uncontrollable cell growth.1,2 It damages cells and
causes them to divide on their own accord which can result into the formation of tumors.
Hundreds of different types of cancer have been identified and they are classified by the
type of cell that is first affected.2

1

Figure 1: Cancer Mortality Worldwide
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Targeting Cancer with Protein Biopharmaceuticals
The birth of biotechnology since the 18th century have recorded massive
improvements in its applications.3 In the 1960s, there was an immediate increase in
research involving the use of biotechnology in pharmaceutical industries. This increase
led to a number of important findings, which gave researchers a better understanding of
the molecular activities of biological systems.4 Scientists also discovered that the human
body has proteins that can fight against pathogenic microbes. This discovery gave rise to
the development of biopharmaceuticals. Furthermore, it led to the increase of new
techniques with the involvement of industrial applications in pharmaceutical areas.
In the 1980s, the word “biopharmaceutical” was first used to describe a class of
therapeutic drugs produced by biotechnological techniques such as genetic engineering.5
Biopharmaceuticals are defined as medicinal products partially or fully manufactured
from biological sources. These sources mainly include proteins and nucleic acids.6
The onset of producing biopharmaceuticals started from making biosynthetic
human insulin using recombinant DNA technology. Its trade name was Humulin and was
officially deemed suitable for therapeutic use in 1982.7 Several biopharmaceuticals have
since been

produced

to

treat

various types

of

diseases

such hemophilia,

thromboembolism, leukemia and more.8
The number of biopharmaceuticals that has being produced for the global
healthcare market has steadily increased since their advent in the 1980s. Among
biopharmaceuticals, protein biopharmaceuticals are the fastest-growing category of drugs
produced, targeting about 200 human diseases. Diseases such as Alzheimer's disease,
some types of cancers, heart disease and diabetes are currently being treated with protein
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biopharamaceuticals.9 In 2013, $199.7 billion was invested globally towards
biopharmaceutical research and development. It is projected that by the year 2020, a total
of $497.9 billion will be invested globally towards biopharmaceuticals research.
There have been massive breakthroughs in the diagnoses and treatment of cancer
in the last few decades. Despite these advances there are still challenges to overcome.
Studies show that tumors have developed resistance against current anticancer therapies.
This increasing resistance necessitates the development of novel therapeutic anticancer
agents. Recent studies have documented the overexpression of proteins such fibroblast
growth factors (FGFs) in certain cancer such as breast cancer.10 The FGFs play important
roles in the metasis and advancement of cancer cells via cell multiplication induced by
FGF and FGF-angiogenesis.
The Super Family of Fibroblast Growth Factors
Armelin discovered fibroblast growth factors in pituitary extracts in 1973.
Research has continued to progress on this class of heparin-binding proteins.11 Due to
continued research, 23 distinct FGFs have been discovered, namely FGF-1 to FGF-23.
FGF-1 and FGF-2 are the most studied members of the super family. The molecular size
of FGFs is between 17 to 34 kDa and they have a common internal core of 140 amino
acids, with 28 of the residues being highly conserved as well as 6 identical amino acids. 12
They are also all β-sheets without disulfide bonds (Fig. 2).13
FGFs are involved in various essential cellular roles. They are important
regulators in fetal development. They stimulate the formation of mesoderm and are
involved in the regulation of cell migration to form the three germ layers. Studies have
shown that FGFs also function as mitogenic agents in variety of cells with mesodermal
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and endodermal origins.14 Other crucial functions such as formation of the midbrain,
lungs and limbs have been associated with FGFs. Their significant involvement in
alveolar formation, branching of trachea and limb development has also been reported.15–
18

Recently, it has being suggested that FGF signaling is important during the early stages

of neural induction in the development of the central nervous system. However, during
the development of the midbrain, cell proliferation induced by FGFs is important in the
formation of the midbrain-hindbrain boundary (MHB). Furthermore, FGFs have
biological functions which include involvement in the process of wound healing,
angiogenesis and also stimulation of cell survival factors: cell migration and
differentiation.19,20 They have also been involved in pathological conditions, mainly
diabetic retinopathy, rheumatoid arthritis and tumor growth. 21 Studies have demonstrated
that the activities of FGFs are activated by two types of receptors on cell surfaces; the
high affinity family of tyrosine kinase FGF receptors known as FGFRs and the low
affinity family of proteoglycans: heparan sulfate and heparin.12

Figure 2: Three dimensional structure of FGF
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High Affinity Binding Fibroblast Growth Factor Receptors
The Fibroblast Growth Factor Receptors (FGFR) family consists of five members,
four of which are transmembrane with tyrosine kinase activity, (FGFRs 1-4) and the fifth
with no tyrosine kinase activity. The FGFRs are about 70% identical in structure and
typically consist of a well conserved extracellular region, an acid box, a transmembrane
domain and an intracellular tyrosine kinase domain. Extracellularly they comprise of
three immunoglobulin-like (Ig-like) domains numbered D1, D2, and D3 with a region inbetween the D1 and D2 of unique acidity known as acid box (Fig. 3). The tyrosine kinase
domain contains both ATP binding and catalytic sites.14,

22

The differences in the

structure and functions of FGFRs are caused by the alternative splicing of FGFR
encoding mRNA and alternate promoter activity which gives rise to receptor isoforms.23
The major FGF binding site on FGFRs is the D2 domain, D3 is known for determining
the specificity of FGFs binding. The function of the D1 domain is not clear, although
some studies suggest that it might inhibit FGF binding.24 Studies have shown that the
majority of FGFs bind and are activated by more than one FGFR.25
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Figure 3: Schematic structure of FGFR showing extracellular domain which contains of
a signal peptide, three IG like domains (D1, D2, and D3), a transmembrane region and an
internal tyrosine kinase domain

Low Affinity Proteoglycan Family Receptors
Researchers have shown that with the help of proteoglycans such as heparin or
heparan sulfate, which function as low affinity cell surface receptors, FGFs are able bind
to FGFRs.15,26 Heparin and heparin sulfates (HS) are glycosaminoglycans. Heparin
consists of complex acidic polysaccharides characterized by a disaccharide repeating unit
of α-d-glucosamine (Fig. 4). They are highly sulfated and negatively charged biological
molecules.27 HS consists of a protein core attached to several carbohydrate moieties.
They are also highly sulfated which makes them negatively charged. Heparins are usually
located on cell surfaces and in the extracellular matrix and providing specific binding
7

sites on cells.26,28 It is well documented that heparin and HS bind to a region of the D2
domain of FGFRs named K18K loop because it is made up of positive amino acids.24
Researchers have shown that there are physiological functions attached to heparin
binding to FGFs. The two most important functions are protecting FGFs from degrading
and creating specific reservoir of the proteins. Some researchers have shown that heparin
interactions with FGFs protect them from heat since these growth factors are very
unstable even at physiological temperature. The specific reservoir of FGFs is for
regulation of FGF signaling which concentrates them so they are available in a large
amount.29 Recently, it has been documented that heparin aids the binding of FGFs to
FGFRs.25

Figure 4: Heparan sulfate
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Signaling Mechanism of FGFs
The binding of heparin or HS with FGF and FGFR to form a ternary complex is
an important step in FGF signaling.29 The stabilization of FGFs is also enhanced by
heparin which is crucial for FGF signal transduction.26 Once the ternary complex is
formed, FGFR dimerization takes place followed by auto phosphorylation of the tyrosine
residue on the FGFR.
A series of downstream signaling takes place consisting of phosphoinositide 3kinase, Ras/mitogen-activated protein kinase (MAPK) among others. The signal
transduction mechanism is shown in Figure 5. It has been proven that in the absence of
cell surface proteoglycan heparan sulphate, a significant reduction in FGFR activity
involving cell proliferation, mitogenesis and wound healing is noticed.30,31
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FGF

FGF

Extracellular

Transmembrane
Intracellular

Figure 5: Signaling Mechanism of FGFs. Formation of ternary complex of FGF: FGFR:
HSPG leading to the activation of intracellular kinase domains and auto phosphorylation
of the tyrosine amino acid residues. Downstream events lead to DNA replication and then
cell proliferation and migration

10

Human Fibroblast Growth Factor-1 (hFGF-1)
Human fibroblast growth factor (hFGF-1) is also known as acidic fibroblast
growth factor because it contains many acidic amino acids like lysine. The hFGF-1 is the
most studied member of the FGF family. The hFGF-1 is a non-glycosylated polypeptide
consisting of 154 amino acids residues made up 12 β strands. It is a powerful mitogen
and is involved in the stimulation of DNA synthesis and cell proliferation in cell lines
such as fibroblasts, myoblasts, chondrocytes.32 It is considered a pro-angiogenic drug
candidate in the treatment of wound healing and peripheral artery diseases.33,34
Various studies have shown that there is overexpression of hFGF-1 in tumors
such as breast cancer. Their interactions with FGF receptors as described in previous
paragraphs are crucial in the cell proliferation and differentiation which in turn promotes
the growth of tumors.10

Objective of Study
Overexpression of FGFs and its receptors (FGFRs) has been associated with the
promotion of several types of tumor cells. hFGF-1 especially has been associated as a
pivotal component in the development of lung and breast cancer among others.
Researchers have come up with different methods such as small molecule drugs
inhibiting the interactions of these proteins with their receptors (FGFRs) which will in
turn inhibit FGF induced cell proliferation in tumorous regions.
New studies show that hFGF-1/FGFRs interactions can be considered an
important target for tumor therapy by designing antagonists capable of modulating their
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interactions in cancer progression. In order to design such antagonists, purified forms of
hFGF-1 and D2 domain (hFGF-1 binding site) is important. The objective of this study is
to show a method for large scale recombinant protein purification using heparin and
Nickel Nitrolotriacetic acid (Ni-NTA) affinity column chromatography. This method of
chromatography is to achieve purification of human fibroblast growth factor-1 and the D2
domain of fibroblast growth factor receptor-2 in biologically active conformations. The
hFGF-1 was also expressed isotopically in the form of 15N hFGF-1.

MATERIALS AND METHODS
12

This chapter consists of the materials and methods used during this study. Table 1 is the
list of all the chemicals used in this study and company they were purchased from.
Materials
The microorganism used in this study was recombinant Escherichia coli [BL21 (DE3)]
This was brought from Invitrogen.

Chemicals

Company

Ammonium chloride

EMD Chemicals

Ammonium sulfate

EMD Chemicals

Ampicillin

Amersco

Brom phenol blue

Allied Chemicals

2-mercatoethanol

J.T Baker

Calcium chloride

EMD Chemicals

Chloramphenicol

Sigma Aldrich

Dextrose

EMD Chemicals

Disodium hydrogen phosphate

EMD Chemicals

Glycerol

EMD Chemicals

Glycine

EMD Chemicals

Heparin sepharose resin

GE Healthcare

Isopropyl β-D-1Thiogalactopyranoside (IPTG)

Amersco

Luria Broth (LB)

Novagen

Monobasic and dibasic sodium phosphate

EMD Chemicals

Magnesium chloride

EMD Chemicals
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Methanol

EMD Chemicals

Ni-NTA resin

GE Healthcare

Potassium sulfate

EMD Chemicals

Potassium di-hydrogen phosphate

EMD Chemicals

Potassium hydrogen phosphate

EMD Chemicals

Brilliant Blue R 250 Dye

Fisher Biotech

Riboflavin

EMD Chemicals

Sodium azide

EMD Chemicals

Sodium chloride

J.T. Baker

Sodium dodecyl sulfate (SDS)

EMD Chemicals

Temed

EMD Chemicals

Thiamine

Acros Organic

Tris Base

Cal Biochem

Trichloroacetic acid

EMD Chemicals

Urea

J.T Baker

Table 1: The list of chemicals used in this study and the respective companies they was
obtained from

The methods and instrumentations used in this study are further discussed in this section
of the chapter.
Methods
Buffer Preparation
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All pH adjustment was achieved using a pH meter
0.5 M Monobasic Buffer (NaH2PO4.2H2O) (FW: 156 g): A sample of 30.00 g
monobasic sodium phosphate was weighed and dissolved in nanopure water of about 400
ml in a conical flask. The total volume was made up to 500 ml and poured into a clean
labelled glass bottle and stored at 23 oC.
0.5 M Dibasic Buffer (Na2HPO4.12H2O) (FW: 358 g): A sample of 35.50 g of dibasic
sodium phosphate was weighed into a conical flask and dissolved in nanopure water of
about 400 ml. The total volume was made up to 500 ml and transferred into a clean
labelled glass bottle and stored at 23 oC.
0.5 M Phosphate Buffer (500 ml): A mixture of 50 ml of 0.5 M monobasic and 450 ml
of 0.5 M dibasic was made (1:9 ratio of monobasic and dibasic). The pH was adjusted to
7.2 and the solution was poured into a labelled clean glass bottle and stored at 23 oC.
10 mM Phosphate Buffer (1 L): A solution of 20 ml 0.5 M phosphate buffer was
measured into a conical flask using a 1 L graduated cylinder. Nanopure water was added
to make up volume to 1 L. This mixture was stirred well and transferred into a clean
labelled glass bottle and pH was adjusted to 7.2.
5 M Sodium Chloride (500 ml): A sample of 146.0 g sodium chloride crystals was
weighed into a conical flask and dissolved with about 400 ml of nanopure water. The
solution was made up to 500 ml and poured into a clean labelled glass bottle.
0.8 M NaCl in 10 mM Phosphate Buffer (500 ml): A solution of 80 ml 5 M sodium
chloride was mixed with about 350 ml of 10 mM phosphate buffer in a conical flask. The
volume was made up to 500 ml with 10 mM phosphate buffer and pH was adjusted to
7.2. The solution was poured into a clean labelled glass bottle.
15

1.5 M NaCl in 10 mM Phosphate Buffer (500 ml): A solution of 150 ml 5 M sodium
chloride was mixed with about 250 ml of 10 mM phosphate buffer in a conical flask. The
volume was made up to 500 ml with 10 mM phosphate buffer and pH was adjusted to
7.2. The solution was poured into a clean labelled glass bottle.
1 M Sodium Azide (100 ml): A sample of 6.500 g of sodium azide was weighed into a
250 ml conical flask and dissolved with about 70 ml of nanopure water. Using a
graduated cylinder, the volume was made up to 100 ml. The solution was poured into a
clean labelled glass bottle.
Dialysis Buffer (4 L): A solution of 80 ml 5 M sodium chloride (100 mM), 80 ml of 0.5
M phosphate buffer (10 mM), 26.4 g of ammonium sulfate (50 mM) and 4 ml of 1 M
sodium azide were measured into a 4 L conical flask. About 3.5 L of nanopure water was
added and the solution was mixed well and total volume was made up to 4 L with
nanopure water and then pH was adjusted to 7.2.

Construction of hFGF-1 and D2 domain of FGFR-2
Human FGF-1 (GenBank #X59065) of residues 14-154 from full length hFGF-1
and D2 domain of human FGFR-2 (GenBank #AK026508) of residues 145-259 from full
length FGFR-2 cDNAs were made following standard procedures. They were cloned into
pJExpress414 vectors (DNA2.0) and transformed into BL21(DE3) E. coli cells for
overexpression.35 The gene sequences were optimized using DNA2.0 codon bias
algorithm to maximize the yield of the proteins prior to cloning.36
Solution for SDS-PAGE

16

Tris (Tris hydroxyl methyl) Amino Methane (pH 8.8): A sample of 24.22 g tris base
was weighed into a conical flask and dissolved in about 150 ml of nanopure water and
mixed well. The solution was made up to 200 ml with nanopure water and pH was
adjusted to 8.8. Solution was transferred to a clean labelled glass bottle and stored at 4 ºC
in a refrigerator.
Tris (Tris hydroxyl methyl) Amino Methane (pH 6.8): A sample of 24.22 g tris base
was weighed into a conical flask and dissolved with about 150 ml of nanopure water and
mixed well. The solution was made up to 200 ml with nanopure water and pH was
adjusted to 6.8. Solution was transferred to a clean labeled glass bottle and stored at 4 ºC
in a refrigerator.
10% Sodium Dodecyl Sulfate: A sample of 4 g of sodium dodecyl sulfate was weighed
into a 50 ml falcon tube and dissolved with 35 ml of nanopure water. The mixture was
vortexed well and the volume made up to 50 ml of nanopure water and stored at room
temperature.
10% Ammonium per sulfate (APS): A sample of 1.000g ammonium per sulfate was
weighed into a 50 ml falcon tube and dissolved with 10 ml of nanopure water; solution
was transferred into a glass bottle and stored at 4ºC in a refrigerator.
Staining Buffer: A sample of 2.500 g R250 dye, 450 ml methanol and 100 ml glacial
acetic acid were weighed and measured respectively into a 1 L conical flask and mixed
well. About 500 ml of nanopure water was added and mixed well; total volume was made
up to 1 L with nanopure water.
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Distaining Buffer: A solution of 150 ml methanol, 75 ml glacial acetic acid and 775 ml
of nanopure water were measured and mixed well in a 1 L conical flask. Solution was
stored at room temperature.
10X Running Buffer Stock: A sample of 30.80 g tris base, 166.0 g glycine, 10.00 g SDS
were weighed into a conical flask and dissolved with about 500 ml of nanopure water and
the solution was mixed well using a magnetic stirrer. The final volume was made up to
1000 ml with nanopure water and mixed well. The solution was stored at room
temperature.
Running Buffer for SDS-PAGE: A solution of 930 ml nanopure water was measured
using a graduated cylinder into a conical flask and 70 ml of 10X running buffer stock was
added and mixed thoroughly.
0.1% Bromo phenol Blue: A sample of 50.00 mg of bromo phenol blue was weighed
and dissolved with 50 ml of nanopure water. The solution was mixed thoroughly and
transferred into a clean glass bottle and stored at room temperature.
Loading Dye Stock: A solution of 0.6 ml of tris base (pH 6.8), 1 ml glycerol and 2 ml
10% SDS were measured and mixed well with 5.4 ml nanopure water. Solution was
stored at room temperature.
2X Loading Dye (500 μl): A solution of 475 μl of loading dye stock was mixed well
with 25 μl 2-mercaptoethanol.
150% Trichloroacetic acid: A sample of 15.00 g of trichloroacetic acid was weighed
and dissolved in 10 ml of nanopure water and mixed thoroughly. Solution was stored at
room temperature.
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8 M Urea: A sample of 9.600 g of urea was weighed into a conical flask and dissolved
with about 15 ml of nanopure water and mixed well. Total volume was made up to 20 ml
with nanopure water and stored at room temperature.
Media Preparation
Luria broth Media (1 L): A sample of 25.00 g of LB broth was weighed out in a 2000
ml conical flask and about 500 ml of nanopure water was added. The solution was mixed
well and using a measuring cylinder it was made up to 1 L and autoclaved.
Minimal Media (500 ml): A sample of 13.00 g of Potassium Dihydrogen Phosphate
(KH2PO4), 10.00 g of Potassium Hydrogen Phosphate (K2HPO4), 9.00 g of Sodium
Hydrogen Phosphate (Na2HPO4), 2.400 g of Potassium Sulfate (K2SO4) and 0.5000 g of
15

N Ammonium Chloride (NH4Cl) were accurately weighed out into a 2000 ml conical

flask and dissolved with about 400 ml of nanopure water and mixed well. The solution is
made to mark of 500 ml with nanopure water, mixed well and autoclaved. When the
media was cooled to room temperature, 400.0 mg of dextrose, 10 μl of 1 M calcium
chloride (CaCl2), 1 ml of 1 M magnesium chloride (MgCl2), 500 μl of 5.000 mg/ml
thiamine, 68 μl of riboflavin, 100 μl of 50.00 mg/ml ampicillin and 100 μl of 34.00
mg/ml chloramphenicol were added.
Expression and solubility of hFGF-1
E. coli cells were transformed with pJExpress414 vector containing the hFGF-1.
The proteins were first grown in 100 ml LB medium containing 1µl/ml of
chloramphenicol and ampicillin. Induction of the proteins was achieved by addition of
0.5 mM/L of Isopropyl-β-D-thiogalactopyranoside (IPTG) once the absorbance of the
growing culture reached about 0.6 at 600 nm. The culture was further incubated at 37 °C
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for 12 more hours until absorbance at 600 nm was about 1.4. The cells were harvested
and lysed by sonication (Fig. 6). The SDS-PAGE analysis of expression and solubility of
hFGF-1 was done.
Purification of recombinant hFGF-1 using heparin affinity column chromatography
Human FGF-1 was expressed in soluble form and the purification was achieved
by heparin sepharose affinity column. The clear soluble fraction of bacterial cell lysate
was loaded onto a heparin sepharose affinity column and incubated at room temperature
for an hour. The hFGF-1 was bound to heparin sepharose in the column and washed with
elution buffers (pH 7.2) of increasing ionic strength; 10 mM phosphate buffer next was
10 mM phosphate buffer containing 0.8 M NaCl, finally with 10 mM phosphate buffer
containing 1.5 M NaCl. The protein was eluted with the buffer containing 1.5 M NaCl
(Fig. 7). The temperature was maintained at about 4 oC throughout the process of
purification. SDS-PAGE analysis of all samples from the elution fraction was done.
Results from the SDS-PAGE analysis that showed the fraction/fractions with the
highest concentrations and single bands were subjected to desalting by dialysis in
phosphate buffer containing 100 mM NaCl (pH 7.2). The conformation and concentration
of the final protein sample was assessed using PerkinElmer spectro-fluorometer and UVVis spectrophotometer respectively.

20
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Figure 6: Schematic representation of hFGF-1 expression
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supernatant
Heparin
hFGF-1
Unwanted proteins
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ionic strength
Start of Dialysis
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intensity on the coomassie gel of SDS-PAGE

Conformational
stability analysis

Figure 7: Schematic representation of hFGF-1 purification by heparin sepharose affinity
chromatography

Expression and solubility of FGFR-2 D2 domain
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E. coli cells were transformed with pJExpress414 vector containing D2. The
proteins were first grown in 100 ml LB medium containing 1µl/ml of chloramphenicol
and ampicillin. Induction of the proteins was achieved by addition of 0.5 mM/L of
Isopropyl-β-D-thiogalactopyranoside (IPTG) once the absorbance of the growing culture
reached about 0.5 at 600 nm. The culture was further incubated at 37 °C for 12 more
hours until absorbance at 600 nm was about 1.4 (Fig. 8). The cells were harvested and
lysed by sonication. SDS-PAGE analysis of the expression and solubility of D2 domain
was done.

Purification of D2 domain of FGFR-2 using Ni-NTA and heparin affinity column
chromatography
The protein lysate from sonication was centrifuged and the supernatant was
discarded because D2 was expressed in inclusion bodies (the insoluble part of bacterial
cell lysate) and so they were in the pellet. Purification was achieved by denaturation of
the inclusion bodies using 20 ml of 8 M urea. The suspension was then centrifuged and
the supernatant loaded onto a nickel affinity column and incubated at room temperature
for one hour. The refolding of the protein was achieved by a stepwise reduction of urea
concentration (8 M to 0 M) and incremental increase of imidazole (20 mM to 500 mM)
since D2 was His-tagged. The protein was eluted by the buffer with 500 mM imidazole in
it. Further purification was facilitated by incubating the 500 mM imidazole fraction onto
a heparin sepharose column and washed with 10 mM phosphate buffer (pH 7.2) to
remove contaminating proteins (Fig. 9). D2 was bound to heparin sepharose in the
column and was eluted with 10 mM phosphate buffer containing 1.5 M NaCl. Results
from the SDS-PAGE that showed the fraction with single band was subjected to desalting
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by dialysis in phosphate buffer containing 100 mM NaCl (pH 7.2). The conformation and
concentration of the final protein sample was assessed using PerkinElmer spectrofluorometer and UV-Vis spectrophotometer respectively.
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Figure 8: Schematic representation of D2 domain of FGFR-2 expression
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Figure 9: Schematic representation of D2 purification by Ni-NTA affinity
chromatography
Heteronuclear Single Quantum Coherence- Nuclear Magnetic Resonance (HSQCNMR)
The 1H-15N HSQC-NMR is a commonly used experiment in protein NMR studies
26

that provides the fingerprint of protein molecules. The spectrum result of the active NMR
protein displays 1H along one axis, while the other axis is devoted to either of the two
different heteronuclear atoms present in an amino acid (13C or

15

N). HSQC-NMR is

useful to detect the binding interface between protein-protein and protein-ligands such as
drugs. This can be achieved by overlapping the HSQC spectrum of the free protein with
the one bound to the ligand, then analyzing for changes in the chemical shifts of some
peaks can be observed.
15

N Labelled Human FGF-1 Expression and Purification
The hFGF-1 were expressed and in order to make them NMR active, the proteins

were grown in

15

N labelled media which was an M9 medium containing

15

NH4Cl.37

Minimal media was prepared as previously discussed. The recombinant E. coli used was
ampicillin and chloramphenicol resistant. Ampicillin and chloramphenicol were added to
the media to inhibit the growth of other bacteria. A preculture of 100 ml minimal media
containing the bacterial cells was grown for about 14 hours. Purification of

15

N labelled

hFGF-1 was done following procedure as unlabeled hFGF-1 purification discussed
previously. After dialysis, the sample was concentrated using Amicon ultra centrifugal
filters. The membranes in the filters were soaked for 1 hour with nanopure water. Next,
they were soaked in dialysis buffer for 30 minutes. The protein sample was transferred
into the filters and parafilm was used to cover them. The tubes were then centrifuged at
7,000 rpm for about 12 minutes. This procedure was continued until sample was
concentrated to 4 ml.
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Supplement bacterial medium
with N15 ammonium chloride

Figure 10: Making N15 Labelled hFGF-1 Molecules

RESULTS AND DISCUSSION
Biopharmaceutical drug research requires an approach for obtaining hFGF-1 and
FGFR in pure forms for research purposes. Next, these purified proteins were studied
28

using several

biophysical techniques to understand their structural-functional

relationship. This is useful developing novel targets to cure diseases these proteins are
associated with.
Expression and Purification of hFGF-1
The hFGF-1 construct used in this present study is 140 amino acids long, and is
derived from the full length human FGF-1. The recombinant E. coli was amplicon and
chloramphenicol resistant hence amplicon and chloramphenicol were added to the media
to inhibit the growth of other bacteria. Addition of Isopropyl β-D-thiogalactopyranoside
(IPTG) to the growing media containing hFGF-1 induced lac operon. This increased the
production of hFGF-1 while suppressing other genes. SDS-PAGE analysis of hFGF-1
expression showed that most of the protein was expressed in the soluble portion of the
media after lysing and centrifugation (Fig. 11). Since hFGF-1 is a positively charged
molecule and heparin is negatively charged, purification was facilitated by heparin
affinity column chromatography. hFGF-1 bound to heparin tightly and the undesired
proteins were removed by first running the wash buffer [10 mM phosphate buffer (pH
7.2)]. With increasing sodium chloride gradient concentration of 0 to 1.5 M, all unwanted
proteins were removed and hFGF-1 was finally eluted with buffer containing 1.5 M
NaCl. SDS-PAGE analysis of purified hFGF-1 showed an intense single band
corresponding to a molecular weight of ~16 kDa. (Fig. 12). This fraction was further
desalted with 100 mM NaCl buffer. Using a PerkinElmer Spectro-fluorometer the
conformation of the purified protein was shown to be in native conditions and well
folded. The concentration of hFGF-1 was quantified using UV-Vis spectroscopy
following Beer’s law equation: A= Ecl, where A is absorbance at 280 nm, E is extinction

29

coefficient value of hFGF-1 which is 1.28, l is path length of the UV cuvette used38. The
total yield of purified hFGF-1 was about 0.82 mg per ml and about 19 mg per one liter
culture. The purified sample was finally allocated into eppendorf tubes and stored at -80
ºC.
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Figure 11: SDS-PAGE analysis of hFGF-1 expression. Lane M represents the molecular
weight marker; lane 1, uninduced sample; lane 2, induced sample; lane 3, lysate of
induced sample insoluble fraction; lane 4, lysate of induced sample soluble fraction
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Figure 12: SDS-PAGE analysis of hFGF-1 purification using heparin column. Lane M,
represents the molecular weight marker; lane 1 represents the protein band contained in
fraction collected as flow through; lane 2, represents the protein band contained in
fraction eluted in 10 mM phosphate buffer; lane 3, represents the protein band contained
in fraction eluted in buffer containing 0.8 M NaCl and 10 mM phosphate buffer; lanes 47, represents the protein bands contained in fractions eluted in buffer 1.5 M NaCl and 10
mM phosphate buffer
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The Expression and Purification of D2 domain of FGFR-2
The D2 domain construct used in this study was 114 amino acids long from the
full length human FGFR-2. SDS-PAGE analysis of the bacterial cells induced by IPTG
showed that most of the protein was expressed in the insoluble fraction of the protein
lysate (inclusion bodies) after sonication and centrifugation (Fig. 13).
The insoluble pellet was dissolved in 8 M urea which denatures and unfolds the
protein. Proteins are denatured by urea by altering the arrangement of water molecules
which makes them move into the hydrophobic core of the protein and weakening the
intermolecular bonds of the peptide. This weakens the secondary and tertiary
conformation of the protein. The denatured D2 was loaded onto a Ni-NTA (Nickel
Nitrilotriacetic acid) affinity column, since D2 was His-tagged causing it to be negatively
charged because of the imidazole rings on histidine. Refolding of the protein was
facilitated by incubating the denatured protein fraction on an Ni-NTA affinity column
and refolding using a linear gradient decrease of urea (8 M to 0 M) and increase of
imidazole (20 mM to 500 mM). The concentration of urea was gradually decreased to
refold the protein in the column while the concentration of imidazole was increased to
elute the protein. The free imidazole in the buffer competes with D2 for nickel. The
column was washed with 20 mM phosphate buffer (pH 7.2) which contained 20 mM, 50
mM, 100 mM imidazole concentrations and finally the protein was eluted in 500 mM
imidazole concentration. Increasing concentrations of imidazole were used for two main
purposes; first, to reduce the concentration of urea to get the protein back into native
conformation. Second, it was used to elute the protein by competing for the positively
charged sites on Ni-NTA column. The partially pure protein was further purified by
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incubating the 500 mM imidazole fraction onto a heparin affinity column. The column
was washed with phosphate buffer; the impurities were eluted by the 10 mM phosphate
buffer (pH 7.2) and 10 mM phosphate buffer containing 0.8 mM sodium chloride (pH
7.2). The D2 domain was eluted with 10 ml phosphate buffer containing 1.5 M sodium
chloride (pH 7.2) and yielded an intense single band on SDS-PAGE corresponding to a
molecular mass of ~ 13 kDa (Fig. 14). Using a PerkinElmer Spectro-fluorometer the
conformation of the purified protein was shown to be in native conditions and wellfolded. The concentration of hFGF-1 was quantified using UV-Vis spectroscopy
following Beer’s law equation: A= Ecl, where A is absorbance at 280 nm, E is extinction
coefficient value of D2 which is 24075 M-1 cm-1, l is path length of the UV cuvette used
38

. The total yield of purified D2 was about 17 mg per 1 liter culture. The purified sample

was finally allocated into eppendorf tubes and stored at -80 ºC.
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Figure 13: SDS-PAGE analysis of D2 domain of FGFR-2 expression. Lane M represents
the molecular weight marker; lane 1 represents the uninduced sample; lane 2 represents
the induced sample; lane 3 represents the lysate of induced sample soluble fraction; lane
4 represents lysate of induced sample insoluble fraction
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Figure 14: SDS-PAGE analysis of D2 domain purification using nickel affinity (lanes 16) and heparin affinity (lanes 7-10) columns. Lane M represents the molecular weight
marker; lane 1 represents the protein band contained in fraction collected as flow
through; lanes 2-5 represent the protein bands contained in fractions eluted in 20 mM, 50
mM, 100 mM, 500 mM imidazole concentration, respectively from the nickel column.
Lane 7-10 represents the fractions collected from heparin column. Lane 7 represents
protein bands contained in fraction collected as flow through; lane 8 represents the
protein bands contained in fraction eluted in 10 mM phosphate buffer; lane 9 represents
the protein band contained in fraction eluted by the 10 mM phosphate buffer with 0.8 M
NaCl concentration; and lane 10 represents the protein bands contained in fraction eluted
in 10 mM phosphate buffer containing 1.5 M NaCl

Expression and Purification of 15 N labelled hFGF-1

36

E. coli cells were grown in 100 ml of minimal media preculture overnight. It was
further grown for about 14 hours. The procedure described previously for the expression
and purification of unlabeled hFGF-1 was followed for the rest of the experiment.
Expressing and purification of the labelled protein was analyzed by SDS-PAGE (Figs. 15
and 16). The yield was quantized by UV-Vis spectroscopy to be about 22 to 25 mg per
500 ml culture.
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1

Figure 15: SDS-PAGE analysis of

2

15

3

4

N labelled hFGF-1 expression. Lane 1 represents

the uninduced sample; lane 2 represents the induced sample; lane 3 represents the lysate
of induced sample insoluble fraction; lane 4 represents the lysate of induced sample
soluble fraction
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Figure 16: SDS-PAGE analysis of

15

N labelled hFGF-1 purification using heparin

column. Lane M represents the molecular weight marker; lane 1 represents the protein
band contained in fraction collected as flow through; lane 2 represents the protein band
contained in fraction eluted in 10 mM phosphate buffer; lane 3 represents the protein
band contained in fraction eluted by the buffer with 0.8 M NaCl and 10 mM phosphate
buffer; lanes 4-7 represent the protein bands contained in fractions eluted in 10 mM
phosphate buffer with 1.5 M NaCl

Biophysical Characterization of Expressed hFGF-1 and D2 domain
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Biophysical characterization of proteins as regards structural studies is to
determine the state and conformation of the protein purified. This gives information
about the structural conformation of the protein if it is in folded, partially folded, or
unfolded state, the purity and the stability of the protein is also provided. Fluorescence
spectroscopy was used to assess the confirmation of the unlabeled hFGF-1, D2 domain
and

15

N labeled hFGF-1. These proteins contain two amino acids that fluoresce:

tryptophan and tyrosine. These amino acid residues have different absorption and
emission wavelengths in the folded and unfolded states which help in tracking the tertiary
structural changes in the protein molecule. The emission spectrum of hFGF-1 at ~ 308
nm in its native state is dominated by a tyrosine emission peak. In the completely
unfolded state, hFGF-1 exhibits an emission spectrum dominated at ~ 350 nm which is
because of fluorescence of a single well-conserved tryptophan at position 121 in the full
form of the primary sequence (Fig. 17).
The well-folded D2 domain has an emission spectrum at between 338 to 342 nm
but in its completely unfolded state it exhibits an emission spectrum dominated at ~ 350
nm (Fig. 18), which is because of fluorescence of the three well-conserved tryptophan
amino acids.

Native hFGF-1
40

Denatured hFGF-1

Figure 17: Intrinsic fluorescence spectra for hFGF-1, I305/I350 ratio ~ 3.5
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Figure 18: Intrinsic fluorescence spectrum for D2 domain

15

N Labelled Human FGF-1 Expression and Purification
42

The same procedure was followed for expression and purification of unlabeled
hFGF-1. Enriching vitamins were included in the media.

HSQC-NMR sample preparation
A 700 MHz spectrometer was used. Concentration of the protein sample analyzed
was 1.6 mg/ml and was prepared in 10 mM phosphate buffer containing 10 mM sodium
chloride (pH 7.2). The NMR data were acquired at temperature of about 25 ± 0.5 ºC. The
spectrum obtained showed that the purified hFGF-1 was in native state and properly
folded (Fig. 20).
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Figure 19: The 1H-15N HSQC spectrum representing the finger-print of the backbone
conformation of hFGF-1
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CONCLUSIONS
Human fibroblast growth factor-1, a prototype of FGF family is a powerful
mitogen that is considered a potent angiogenic drug candiaite. There have being reports
of overexpression of hFGF-1 in cancers such as breast cancer. The protein binds mainly
to the D2 domain of FGFRs. These two heparin binding proteins were successfully
expressed and purified. Human FGF-1 was expressed in the soluble fraction of the
bacterial lysate and was purified using heparin sepharose affinity chromatography. N 15
labelled hFGF-1 was also expressed and purified. The D2 domain of FGFR was
expressed in the insoluble fraction of the bacterial lysate and was purified using nickel
affinity chromatography. SDS-PAGE analysis of both proteins showed that were
expressed in pure forms. Data from fluorsecence analysis showed that the proteins were
properly folded and were in biologically active conformations. The total yield of hFGF-1
was 32.7 mg per 1 litre culture. The yield of D2 domain was 18 mg per 1 litre culture.
The findings of this study will facilitate research towards understanding the
regulation of heparin binding proteins mediated biological activities. Since hFGF1/FGFRs interactions have been considered a target for cancer therapy, the efforts to
develop antagonists targeting this interaction have been on an increase; hence, producing
pure form of these proteins will enhance research in the area of cancer therapy.
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FUTURE STUDIES
There has been an increase of research in the area of protein biopharmaceuticals
development. Proteins such as fibroblast growth factors and their receptors, particularly
human FGF-1, as stated previously are important target in cancer therapy.

The

availability of purified forms of these proteins will enhance research about them. The
hFGF-1’s structure and interactions with its receptors can be studied using various
biophysical techniques such as proteolytic digestion, biacore. Data from these techniques
would be useful in the development of strategies to produce protein biopharmaceuticals.
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